WEBINAR: Preclinical Prostate Cancer Models: Which One Is Right For You?

Wednesday November 28th 10am ET | Thursday November 29th 6am ET

Presented by Dr Rajendra Kumari this webinar deep dives into the range of preclinical prostate cancer models needed for a comprehensive drug discovery program. Understand the key advantages and limitations of prostate cancer cell line and patient-derived xenografts, and how to choose the correct immunocompetent model for prostate cancer immunotherapy development.

NEW CLIENT PROMOTION: DiscoverCrown - Save 10% on Your First Translational Dysmetabolic Rodent or NHP Study

Save 10% on your first study with our translational rodent or NHP models of diabetes, obesity, renal disease, and NAFLD/NASH. Discover CrownBio's winning combination of translational models and unparalleled scientific expertise today!

Advance Your Prostate Cancer Drug Development with Translational Preclinical Models

Drive forward your research during Movember with our in vitro, in vivo, and immuno-oncology models for prostate cancer. Discover how our range of hormone responsive and castrate-resistant cell lines, xenografts, and PDX, as well as unique I/O models, can advance your drug discovery today.

Preview our 10 ENA 2018 Scientific Posters

November 13-16, The Convention Centre Dublin, Ireland, Booth A9

Join us at the 30th EORTC-NCI-AACR Symposium where we'll be presenting 10 posters on our unique oncology and immuno-oncology models and platforms. Stop by Booth A9 during the conference to discuss all your preclinical drug development needs.

WHITE PAPER: New Advancements in Preclinical Prostate Cancer PDX Models

Discover a new panel of prostate cancer patient-derived xenografts for more translational preclinical studies. Explore the development and characterization of these models, including validation with standard of care chemotherapy and targeted agents, and how they help to overcome current prostate cancer preclinical challenges.

ON DEMAND WEBINAR: Patient-Derived Xenografts as Models for Metastatic Breast Cancer and Preclinical Therapy Testing

Presented by Dr Alana Welm, Huntsman Cancer Institute this webinar explores a collection of highly translational breast cancer patient-derived xenograft (PDX) models. Learn about the benefits PDX models bring to breast cancer preclinical research, and their use in evaluating new cancer therapies.

NEW WHITE PAPER: Immunocompetent Murine Models

A Guide to Understanding their Place in Immuno-Oncology Drug Discovery

Discover the optimum applications for commonly used mouse models in immuno-oncology drug development. Learn more about the main advantages and limitations of GEMM, syngeneic, and murine tumor homograft models, and how to choose the best model for each step of a comprehensive and flexible drug discovery program.

WHITE PAPER: NAFLD/NASH: Accelerating Drug Discovery with an Improved Metabolic Dysregulation Model

Enhance your NASH drug development programs with a new highly translational mouse model, combining human disease-relevant dysmetabolic and liver pathology features. Learn why improved preclinical models are needed, and how they can save you valuable study time and resouces.

ON DEMAND WEBINAR: New Advancements in Preclinical Prostate Cancer PDX Models

Presented by Dr Rajendra Kumari this webinar explores a new panel of highly translational prostate cancer patient-derived xenograft (PDX) models. Learn how PDX models provide a more clinically relevant platform for studying prostate cancer, and how the development and validation of these models is improving preclinical prostate cancer drug discovery.

WHITE PAPER: The Importance of Using an Isotype Control

Reliably determine specificity versus background for precision drug development assays. Are you using the correct isotype controls for precise data analysis? Learn best practice and view performance differences when using isotype controls versus other alternatives.

ON DEMAND WEBINAR: NAFLD/NASH: Strategies for Accelerating Drug Discovery with an Improved Metabolic Dysregulation Model

Catch up with our webinar supporting the 1st International NASH Day, and explore a new highly translational mouse model for NAFLD/NASH with concurrent metabolic dysregulation. Dr Judith Gorkski presents characterization and case study data showing how the FATZO mouse can accelerate the preclinical discovery of new NASH treatments.

Missed us at ADA 2018?

Download our scientific posters covering the latest research on cardiac dysfunction and immune cell response in our unique spontaneously diabetic rodent models from the ADA Scientific Sessions 2018.

WHITE PAPER: Exploring Translational Capabilities of PDX Models across In Vivo, In Vitro, and Ex Vivo Applications

Enhance your early stage oncology and immuno-oncology drug development through expanded PDX model use. Learn more about humanized PDX for I/O studies, and explore PDX-derived cell lines and 3D PDX screening panels for in vitro/ex vivo assays, for a fully integrated preclinical research continuum.

ON DEMAND WEBINAR: Murine Immuno-Oncology Models: A Head-to-Head Comparison Between Syngeneics and Tumor Homografts

Presented by Dr Toni Jun, this webinar explores immunocompetent murine immuno-oncology models, with a direct comparison between syngeneics and murine tumor homografts. Learn how to choose between these model types for immuno-oncology applications, exploit model specific features and minimize limitations, as well as how to use these models to help predict patient response to immunotherapy.

Missed us at AACR 18?

Download our 13 scientific posters covering a wide variety of preclinical oncology and immuno-oncology platforms including NGS and transcriptomic PDX analysis, novel murine homograft models, as well as PBMC and humanized drug target models for immunotherapy assessment.

ON DEMAND WEBINAR: Microbiome Drug Development with Whole Communities and Defined Consortia

Presented by Dr. Joseph Maxwell of Finch Therapeutics, this webinar explores how to identify key inflammatory diseases for microbiome therapies and tailor drug development towards selected or whole community microbiota using a human-first platform. Learn more about the microbiota's role in IBD, Crohn's, and other diseases, how specific microbes drive clinical phenotypes, and novel approaches to customizing microbiome drug development.

ON DEMAND WEBINAR: Exploring Translational Capabilities of PDX Models across In Vivo, In Vitro, and Ex Vivo Applications

Presented by Dr John MacDougall, this webinar introduces the integrated use of patient-derived xenograft (PDX) models across preclinical research for more translational studies. Learn more on the importance of using highly translational preclinical cancer models, leveraging the benefits and limitations of in vitro, ex vivo, and in vivo PDX study types, and how this variety of platforms can be used for immuno-oncology studies.

ON DEMAND WEBINAR: In Vitro and Ex Vivo Assays to Accelerate Immuno-Oncology Drug Discovery

Presented by Dr Toni Jun, this webinar introduces a one stop, integrated in vitro/ex vivo I/O assay plaform designed to effciently progress immunotherapy drug development. Learn how to monitor and assess TIL populations and functions, explore the microbiome's role in immunotherapy, and understand a wide range of functional characteristics across the I/O field including tumor microenvironment regulation.

ON-DEMAND WEBINAR: Interrogating Syngeneic Models in Large Scale, How to Use Immunoprofiling Data to Improve your Studies

Presented by Dr Henry Li, this webinar explores the detailed data analysis behind the industry's first large-scale, staggered, syngeneic screening platform for immunotherapy development. Learn how this platform can improve efficiency and reproducibility while reducing cost, how comprehensive immunophenotyping and profiling data is used to address key study design questions, and how RNAseq and FACS/IHC analysis are used for biomarker discovery.

WHITE PAPER: Immuno-Oncology - 3 Strategies for Applying Humanized Models

Enhance your humanized mouse immuno-oncology studies through a deeper understanding of model immunological features and optimized uses. Learn more about immune system humanization strategies, and how these result in different models with contrasting features and limitations, then explore model applications through cancer pharmacology case studies.

Get Your Free Poster

Learn more about the world's largest patient-derived xenograft (PDX) collection. Download or request a poster today.

Watch Henry Li present EORTC 17 Short Talk

Hear Dr Henry Li, Vice President of Biomarker and Diagnostic Technology present our AACR-NCI-EORTC 2017 selected Short Talk titled 'Transcriptomic analysis of patient-derived xenografts reveals heterogeneity in human and mouse stroma/immune compartments'

ON DEMAND WEBINAR: Clinically Relevant Cell-Based Solutions for Target Identification

Learn how to leverage CrownBio's integrated Oncology Portfolio to advance your Target Identification studies. Watch our webinar presented by Michelle Mack.

NEW WHITE PAPER: The Ultimate Guide to Mouse Clinical Trials

Transform your preclinical oncology drug development, with mouse clinical trials using patient-derived xenograft (PDX) models. Learn how the different types of MCT are executed, which is the best fit for your specific drug discovery program, and how they provide the perfect framework for biomarker discovery.

ON DEMAND WEBINAR: How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology

Presented by Dr. Keefe Chng and Dr Judith Gorski this webinar will help guide you through a study design process that will enable the greatest opportunity to generate robust, high-quality data, that gives maximum confidence to select new drug candidates and regulatory submissions.

NEW WHITE PAPER: Translational Platforms to Model Pre-Diabetes, Diabetes, and Diabetic Complications

This White Paper explores a unique platform of highly translational models recapitulating multiple aspects of disease progression as seen in humans, for preclinical efficacy studies.

Clarity with

Recognize your next clinical candidate when you see it.

Our Translational Platforms enable our clients to identify the right patients for the right treatment. Having models which more accurately mimic human disease and population dynamics are key to successfully translating promising compounds into successful clinical candidates, whether treating Oncology or Diabetes related diseases.

Magnify your

Understand the mechanisms of disease.

Our scientific acumen and experience will give you a deeper understanding of not just the pharmacological profile of your compound, but more importantly, a clear understanding of which compounds to progress into the clinic. Take a look at our publications to get a deeper understanding of the depth of our scientific expertise.

Begin with the
end insight

Connecting science to patients.

We help our clients solve some of today's most pressing problems in oncology, cardiovascular, and metabolic disease by answering some of the most challenging questions about human biology.


Models of Obesity


CrownBio’s preclinical Translational Technology Platforms provide spontaneous & diet-induced obesity (DIO) models, to support the transition of new agents into the clinic.

Learn More


Oncology Databases


Our unique databases provide a curated source of well-characterized models available to use for drug discovery including PDX models, cell lines, and syngeneic models.

Learn More


Diabetes Models


Models of both Type 1 and Type 2 diabetes, including conventional, as well as unique, highly translatable models for in vivo efficacy studies of antidiabetic agents.

Learn More

Latest from our Blog

November 14, 2018

Humanized Immuno-Oncology Model Update: ENA 2018

This week, at ENA Dublin 2018, we’re presenting new data from our novel humanized in vivo preclinical platforms. This blog recaps all the new data on double knock-in humanized drug target models and our PBMC-humanized system.

Read More

November 14, 2018

Humanized Immuno-Oncology Model Update: ENA 2018

This week, at ENA Dublin 2018, we’re presenting new data from our novel humanized in vivo...

Read More

October 24, 2018

PDX Study Investigates Cetuximab for Esophageal Cancer

Esophageal cancer patients lack targeted agent treatment options, leaving them with a poor...

Read More

October 16, 2018

Humanized Mouse Models for Immunotherapy Research

Humanized mouse models simulate real patient responses for the evaluation of immunotherapeutic...

Read More

October 11, 2018

Tumor Homograft Model Generation: Dissociated Tumor Cells vs Tumor Fragments

Novel murine immunocompetent models are needed to overcome issues with commonly used syngeneic...

Read More

October 9, 2018

Why PDX Are Needed for Metastatic Breast Cancer Research

Metastatic breast cancer is currently incurable, though preclinical research is ongoing....

Read More

Upcoming Events

November 9 - 13, 2018

The Liver Meeting

San Francisco, CA - Booth #243

November 13 - 16, 2018

30th EORTC-NCI-AACR Symposium

Dublin, Ireland - Booth A9

November 19, 2018

NC3Rs and Cell and Gene Therapy Catapult Workshop: Animal, In Vitro and Computational Models for Preclinical Analysis of Cell-Based Cancer Therapies


November 27 - 30, 2018

3rd Annual World Preclinical Congress Europe

Lisbon, Portugal

Wednesday November 28th 10am ET     Thursday November 29th 6am ET

Webinar - Preclinical Prostate Cancer Models: Which One is Right For You?